10-Year Experience With I-125 Prostate Brachytherapy at the Princess Margaret Hospital: Results for 1,100 Patients

Crook, Juanita; Borg, Jette; Evans, Andrew; Toi, Ants; Saibishkumar, Elantholi P.; Fung, Sharon; Ma, Clement

doi:10.1016/j.ijrobp.2010.04.038

Cited by 100 publications

(46 citation statements)

References 39 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Biochemical disease‐free survival rates have now been reported for this procedure for extended follow‐up periods 14, 15, 16, 17, 18, 19, 20, 21. Similar results are also available in a Canadian context 22, 23, 24, 25…”

Section: System Descriptionsupporting

confidence: 55%

See 1 more Smart Citation

COMP report: CPQR technical quality control guidelines for low‐dose‐rate permanent seed brachytherapy

Beaulieu¹,

Radford

Villarreal-Barajas

2018

J Applied Clin Med Phys

View full text Add to dashboard Cite

The Canadian Organization of Medical Physicists (COMP), in close partnership with the Canadian Partnership for Quality Radiotherapy (CPQR) has developed a series of Technical Quality Control (TQC) guidelines for radiation treatment equipment. These guidelines outline the performance objectives that equipment should meet in order to ensure an acceptable level of radiation treatment quality. The TQC guidelines have been rigorously reviewed and field tested in a variety of Canadian radiation treatment facilities. The development process enables rapid review and update to keep the guidelines current with changes in technology. This article contains detailed performance objectives and safety criteria for low‐dose‐rate (LDR) permanent seed brachytherapy.

show abstract

Section: System Descriptionsupporting

confidence: 55%

“…However, TIPPB alone is a treatment option for some low‐tier intermediate risk prostate cancer patients and can also be used as a boost modality 23, 24, 25…”

Section: System Descriptionmentioning

confidence: 99%

COMP report: CPQR technical quality control guidelines for low‐dose‐rate permanent seed brachytherapy

Beaulieu¹,

Radford

Villarreal-Barajas

2018

J Applied Clin Med Phys

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] The aim of the present study was to realize the first Italian multicentre low-dose-rate prostate BT data collection, reporting the selection criteria, implant parameters and biochemical outcome of patients treated in Italy using this modality and comparing them with other multi-institutional reports. [5][6][7][8][9][10] For this purpose, 11 Italian community and academic hospitals ( Figure 1) pooled their data to generate a large patient cohort involving 2237 patients treated with LDR-BT over a period of 14 years, now with a minimum follow-up of 2 years.…”

Section: Introductionmentioning

confidence: 99%

Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions

Fellin¹,

Mirri²,

Santoro³

et al. 2016

BJR

View full text Add to dashboard Cite

OBJECTIVE:\ud Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure.\ud METHODS:\ud Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes.\ud RESULTS:\ud Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT.\ud CONCLUSION:\ud This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer.\ud ADVANCES IN KNOWLEDGE:\ud Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome

show abstract

“…The actuarial 7-year PRFS was 95.2%. 27 A recently published analysis on 96 men <55 year of age at the time of implant reports an actuarial 7-year PRFS rate of 98.9%. 28 …”

Section: Ontariomentioning

confidence: 99%

“…40 PMH published a report on 1111 men with follow-up ranging to over 9 years, with 82% retaining satisfactory erectile function beyond 5 years. 27,28,33 For men ≤55 at the time of their prostate brachytherapy, and at a median follow-up >5 years, erectile function was maintained in 93%, with 45% using phosphodiesterase-5 inhibitors. 28 Crook and colleagues prospectively collected quality of life outcomes in 190 patients who underwent either radical prostatectomy or brachytherapy in Ontario.…”

Section: Ldr Side Effectsmentioning

confidence: 99%

Canadian Prostate Brachytherapy in 2012

Keyes

Crook

Morris

et al. 2013

CUAJ

Self Cite

View full text Add to dashboard Cite

Prostate brachytherapy can be used as a monotherapy for low-and intermediate-risk patients or in combination with external beam radiation therapy (EBRT) as a form of dose escalation for selected intermediate-and high-risk patients. Prostate brachytherapy with either permanent implants (low dose rate [LDR]) or temporary implants (high dose rate [HDR]) is emerging as the most effective radiation treatment for prostate cancer. Several large Canadian brachytherapy programs were established in the mid-to late-1990s. Prostate brachytherapy is offered in British Columbia, Alberta, Manitoba, Ontario, Quebec and New Brunswick. We anticipate the need for brachytherapy services in Canada will significantly increase in the near future. In this review, we summarize brachytherapy programs across Canada, contemporary eligibility criteria for the procedure, toxicity and prostate-specific antigen recurrence free survival (PRFS), as published from Canadian institutions for both LDR and HDR brachytherapy.

show abstract

10-Year Experience With I-125 Prostate Brachytherapy at the Princess Margaret Hospital: Results for 1,100 Patients

Cited by 100 publications

References 39 publications

COMP report: CPQR technical quality control guidelines for low‐dose‐rate permanent seed brachytherapy

COMP report: CPQR technical quality control guidelines for low‐dose‐rate permanent seed brachytherapy

Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions

Canadian Prostate Brachytherapy in 2012

Contact Info

Product

Resources

About